Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction

  • Protocol
  • Intervention

Authors

  • Taghride Dahhan,

    Corresponding author
    1. Academic Medical Centre, University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands
    • Taghride Dahhan, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands. t.dahhan@amc.uva.nl.

    Search for more papers by this author
  • Eva Balkenende,

    1. Academic Medical Centre, University of Amsterdam, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands
    Search for more papers by this author
  • Madelon van Wely,

    1. Academic Medical Centre, University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands
    Search for more papers by this author
  • Sabine Linn,

    1. Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, Netherlands
    Search for more papers by this author
  • Mariëtte Goddijn

    1. Academic Medical Centre, University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effect of tamoxifen or letrozole in addition to standard controlled ovarian stimulation (COS) protocols on the breast cancer-free interval in premenopausal women with breast cancer who undergo COS for embryo or oocyte cryopreservation.